BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 37580664)

  • 1. Evaluating public interest in herpes zoster in Germany by leveraging the internet: a retrospective search data analysis.
    Kain A; Tizek L; Wecker H; Wallnöfer F; Biedermann T; Zink A
    BMC Public Health; 2023 Aug; 23(1):1546. PubMed ID: 37580664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leveraging web search data in Germany to identify unmet needs of contraceptives on a population-based level: A longitudinal retrospective study.
    Steiner C; Wecker H; Tizek L; Ziehfreund S; Preis S; Pfister K; Oberländer V; Biedermann T; Zink A
    Womens Health (Lond); 2024; 20():17455057241256919. PubMed ID: 38817049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence and costs of herpes zoster and postherpetic neuralgia in German adults aged ≥50 years: A prospective study.
    Schmidt-Ott R; Schutter U; Simon J; Nautrup BP; von Krempelhuber A; Gopala K; Anastassopoulou A; Guignard A; Curran D; Matthews S; Espié E
    J Infect; 2018 May; 76(5):475-482. PubMed ID: 29428228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Herpes zoster incidence in Germany - an indirect validation study for self-reported disease data from pretest studies of the population-based German National Cohort.
    Caputo M; Horn J; Karch A; Akmatov MK; Becher H; Braun B; Brenner H; Castell S; Fischer B; Giani G; Günther K; Hoffmann B; Jöckel KH; Keil T; Klüppelholz B; Krist L; Leitzmann MF; Lieb W; Linseisen J; Meisinger C; Moebus S; Obi N; Pischon T; Schipf S; Schmidt B; Sievers C; Steinbrecher A; Völzke H; Mikolajczyk R
    BMC Infect Dis; 2019 Jan; 19(1):99. PubMed ID: 30700258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany.
    Ultsch B; Weidemann F; Reinhold T; Siedler A; Krause G; Wichmann O
    BMC Health Serv Res; 2013 Sep; 13():359. PubMed ID: 24070414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of the potential public health impact of Herpes Zoster vaccination in Germany.
    Curran D; Van Oorschot D; Varghese L; Oostvogels L; Mrkvan T; Colindres R; von Krempelhuber A; Anastassopoulou A
    Hum Vaccin Immunother; 2017 Oct; 13(10):2213-2221. PubMed ID: 28708959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost of shingles: population based burden of disease analysis of herpes zoster and postherpetic neuralgia.
    Friesen KJ; Chateau D; Falk J; Alessi-Severini S; Bugden S
    BMC Infect Dis; 2017 Jan; 17(1):69. PubMed ID: 28086817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Public health impact of herpes zoster vaccination on older adults in Hong Kong.
    Chan PKS; Wong MCS; Chan M; Ching K; Giannelos N; Ng C
    Hum Vaccin Immunother; 2023 Dec; 19(1):2176065. PubMed ID: 36854447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
    Pellissier JM; Brisson M; Levin MJ
    Vaccine; 2007 Nov; 25(49):8326-37. PubMed ID: 17980938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increasing incidence associated with herpes zoster infection in British Columbia, Canada.
    Marra F; Chong M; Najafzadeh M
    BMC Infect Dis; 2016 Oct; 16(1):589. PubMed ID: 27765026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zoster Vaccine and the Risk of Postherpetic Neuralgia in Patients Who Developed Herpes Zoster Despite Having Received the Zoster Vaccine.
    Tseng HF; Lewin B; Hales CM; Sy LS; Harpaz R; Bialek S; Luo Y; Jacobsen SJ; Reddy K; Huang PY; Zhang J; Anand S; Bauer EM; Chang J; Tartof SY
    J Infect Dis; 2015 Oct; 212(8):1222-31. PubMed ID: 26038400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can crowdsourced data help to optimize atopic dermatitis treatment? Comparing web search data and environmental data in Germany.
    Mick A; Tizek L; Schielein M; Zink A
    J Eur Acad Dermatol Venereol; 2022 Apr; 36(4):557-565. PubMed ID: 34921466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Community and patient values for preventing herpes zoster.
    Lieu TA; Ortega-Sanchez I; Ray GT; Rusinak D; Yih WK; Choo PW; Shui I; Kleinman K; Harpaz R; Prosser LA
    Pharmacoeconomics; 2008; 26(3):235-49. PubMed ID: 18282017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of a vaccination program for the prevention of herpes zoster and post-herpetic neuralgia in adults aged 50 and over in Germany.
    Préaud E; Uhart M; Böhm K; Aidelsburger P; Anger D; Bianic F; Largeron N
    Hum Vaccin Immunother; 2015; 11(4):884-96. PubMed ID: 25933182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term efficacy data for the recombinant zoster vaccine: impact on public health and cost effectiveness in Germany.
    Curran D; Van Oorschot D; Matthews S; Hain J; Salem AE; Schwarz M
    Hum Vaccin Immunother; 2021 Dec; 17(12):5296-5303. PubMed ID: 34905463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Herpes zoster in Germany: quantifying the burden of disease.
    Ultsch B; Siedler A; Rieck T; Reinhold T; Krause G; Wichmann O
    BMC Infect Dis; 2011 Jun; 11():173. PubMed ID: 21679419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Atopic dermatitis-identifying needs in the German population by internet search queries].
    Tizek L; Schielein MC; Tizek L; Zink A
    Hautarzt; 2022 Jun; 73(6):475-484. PubMed ID: 35294564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How large could the public health impact of introducing recombinant zoster vaccination for people aged ≥50 years in five Latin American countries be?
    Han R; Gomez JA; de Veras B; Pinto T; Guzman-Holst A; Nieto J; van Oorschot DAM
    Hum Vaccin Immunother; 2023 Dec; 19(1):2164144. PubMed ID: 36821856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Herpes zoster and postherpetic neuralgia in Catalonia (Spain).
    Salleras L; Salleras M; Salvador P; Soldevila N; Prat A; Garrido P; Domínguez A
    Hum Vaccin Immunother; 2015; 11(1):178-84. PubMed ID: 25483532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the effect of the herpes zoster vaccination programme 3 years after its introduction in England: a population-based study.
    Amirthalingam G; Andrews N; Keel P; Mullett D; Correa A; de Lusignan S; Ramsay M
    Lancet Public Health; 2018 Feb; 3(2):e82-e90. PubMed ID: 29276017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.